Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer

Christopher J. Riley, Kevin P. Engelhardt, Jose W. Saldanha, Wenqing Qi, Laurence S. Cooke, Yingting Zhu, Satya T. Narayan, Kishore Shakalya, Kimiko Delia Croce, Ivan G. Georgiev, Raymond B Nagle, Harinder D. Garewal, Daniel D. Von Hoff, Daruka Mahadevan

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDA) is a lethal disease, with surgery being the only curative modality for localized disease, and gemcitabine with or without erlotinib remains the standard of therapy for unresectable or metastatic disease. CEACAM6 is overexpressed in human PDA independent of stage or grade and causes anoikis resistance when dysregulated. Because murine monoclonal antibody 13-1 possesses target-specific cytotoxicity in human PDA cell lines, we designed a humanized anti-CEACAM6 single-chain variable fragment (scFv) based on monoclonal antibody 13-1. PEGyIation of the glycine-serine linker was used to enhance plasma half-life. These scFvs bound CEACAM6 with high affinity, exhibited cytotoxic activity, and induced dose-dependent poly(ADP-ribose) polymerase cleavage. Murine PDA xenograft models treated with humanized scFv alone elicited tumor growth inhibition, which was enhanced in combination with gemcitabine. Immunohistochemistry showed significant apoptosis, with inhibition of angiogenesis and proliferation, and preservation of the target. Collectively, our results have important implications for the development of novel anti-body-based therapies against CEACAM6 in PDA. fCaHBBFfles.

Original languageEnglish (US)
Pages (from-to)1933-1940
Number of pages8
JournalCancer Research
Volume69
Issue number5
DOIs
StatePublished - Mar 1 2009

Fingerprint

Single-Chain Antibodies
Pancreatic Neoplasms
gemcitabine
Adenocarcinoma
Monoclonal Antibodies
Anoikis
Therapeutics
Poly(ADP-ribose) Polymerases
Heterografts
Glycine
Serine
Half-Life
Immunohistochemistry
Apoptosis
Cell Line
Growth
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Riley, C. J., Engelhardt, K. P., Saldanha, J. W., Qi, W., Cooke, L. S., Zhu, Y., ... Mahadevan, D. (2009). Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer. Cancer Research, 69(5), 1933-1940. https://doi.org/10.1158/0008-5472.CAN-08-2707

Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer. / Riley, Christopher J.; Engelhardt, Kevin P.; Saldanha, Jose W.; Qi, Wenqing; Cooke, Laurence S.; Zhu, Yingting; Narayan, Satya T.; Shakalya, Kishore; Croce, Kimiko Delia; Georgiev, Ivan G.; Nagle, Raymond B; Garewal, Harinder D.; Von Hoff, Daniel D.; Mahadevan, Daruka.

In: Cancer Research, Vol. 69, No. 5, 01.03.2009, p. 1933-1940.

Research output: Contribution to journalArticle

Riley, CJ, Engelhardt, KP, Saldanha, JW, Qi, W, Cooke, LS, Zhu, Y, Narayan, ST, Shakalya, K, Croce, KD, Georgiev, IG, Nagle, RB, Garewal, HD, Von Hoff, DD & Mahadevan, D 2009, 'Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer', Cancer Research, vol. 69, no. 5, pp. 1933-1940. https://doi.org/10.1158/0008-5472.CAN-08-2707
Riley, Christopher J. ; Engelhardt, Kevin P. ; Saldanha, Jose W. ; Qi, Wenqing ; Cooke, Laurence S. ; Zhu, Yingting ; Narayan, Satya T. ; Shakalya, Kishore ; Croce, Kimiko Delia ; Georgiev, Ivan G. ; Nagle, Raymond B ; Garewal, Harinder D. ; Von Hoff, Daniel D. ; Mahadevan, Daruka. / Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer. In: Cancer Research. 2009 ; Vol. 69, No. 5. pp. 1933-1940.
@article{b286200423b543a89a71d38d20ec2cdb,
title = "Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer",
abstract = "Pancreatic ductal adenocarcinoma (PDA) is a lethal disease, with surgery being the only curative modality for localized disease, and gemcitabine with or without erlotinib remains the standard of therapy for unresectable or metastatic disease. CEACAM6 is overexpressed in human PDA independent of stage or grade and causes anoikis resistance when dysregulated. Because murine monoclonal antibody 13-1 possesses target-specific cytotoxicity in human PDA cell lines, we designed a humanized anti-CEACAM6 single-chain variable fragment (scFv) based on monoclonal antibody 13-1. PEGyIation of the glycine-serine linker was used to enhance plasma half-life. These scFvs bound CEACAM6 with high affinity, exhibited cytotoxic activity, and induced dose-dependent poly(ADP-ribose) polymerase cleavage. Murine PDA xenograft models treated with humanized scFv alone elicited tumor growth inhibition, which was enhanced in combination with gemcitabine. Immunohistochemistry showed significant apoptosis, with inhibition of angiogenesis and proliferation, and preservation of the target. Collectively, our results have important implications for the development of novel anti-body-based therapies against CEACAM6 in PDA. fCaHBBFfles.",
author = "Riley, {Christopher J.} and Engelhardt, {Kevin P.} and Saldanha, {Jose W.} and Wenqing Qi and Cooke, {Laurence S.} and Yingting Zhu and Narayan, {Satya T.} and Kishore Shakalya and Croce, {Kimiko Delia} and Georgiev, {Ivan G.} and Nagle, {Raymond B} and Garewal, {Harinder D.} and {Von Hoff}, {Daniel D.} and Daruka Mahadevan",
year = "2009",
month = "3",
day = "1",
doi = "10.1158/0008-5472.CAN-08-2707",
language = "English (US)",
volume = "69",
pages = "1933--1940",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer

AU - Riley, Christopher J.

AU - Engelhardt, Kevin P.

AU - Saldanha, Jose W.

AU - Qi, Wenqing

AU - Cooke, Laurence S.

AU - Zhu, Yingting

AU - Narayan, Satya T.

AU - Shakalya, Kishore

AU - Croce, Kimiko Delia

AU - Georgiev, Ivan G.

AU - Nagle, Raymond B

AU - Garewal, Harinder D.

AU - Von Hoff, Daniel D.

AU - Mahadevan, Daruka

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Pancreatic ductal adenocarcinoma (PDA) is a lethal disease, with surgery being the only curative modality for localized disease, and gemcitabine with or without erlotinib remains the standard of therapy for unresectable or metastatic disease. CEACAM6 is overexpressed in human PDA independent of stage or grade and causes anoikis resistance when dysregulated. Because murine monoclonal antibody 13-1 possesses target-specific cytotoxicity in human PDA cell lines, we designed a humanized anti-CEACAM6 single-chain variable fragment (scFv) based on monoclonal antibody 13-1. PEGyIation of the glycine-serine linker was used to enhance plasma half-life. These scFvs bound CEACAM6 with high affinity, exhibited cytotoxic activity, and induced dose-dependent poly(ADP-ribose) polymerase cleavage. Murine PDA xenograft models treated with humanized scFv alone elicited tumor growth inhibition, which was enhanced in combination with gemcitabine. Immunohistochemistry showed significant apoptosis, with inhibition of angiogenesis and proliferation, and preservation of the target. Collectively, our results have important implications for the development of novel anti-body-based therapies against CEACAM6 in PDA. fCaHBBFfles.

AB - Pancreatic ductal adenocarcinoma (PDA) is a lethal disease, with surgery being the only curative modality for localized disease, and gemcitabine with or without erlotinib remains the standard of therapy for unresectable or metastatic disease. CEACAM6 is overexpressed in human PDA independent of stage or grade and causes anoikis resistance when dysregulated. Because murine monoclonal antibody 13-1 possesses target-specific cytotoxicity in human PDA cell lines, we designed a humanized anti-CEACAM6 single-chain variable fragment (scFv) based on monoclonal antibody 13-1. PEGyIation of the glycine-serine linker was used to enhance plasma half-life. These scFvs bound CEACAM6 with high affinity, exhibited cytotoxic activity, and induced dose-dependent poly(ADP-ribose) polymerase cleavage. Murine PDA xenograft models treated with humanized scFv alone elicited tumor growth inhibition, which was enhanced in combination with gemcitabine. Immunohistochemistry showed significant apoptosis, with inhibition of angiogenesis and proliferation, and preservation of the target. Collectively, our results have important implications for the development of novel anti-body-based therapies against CEACAM6 in PDA. fCaHBBFfles.

UR - http://www.scopus.com/inward/record.url?scp=62449303723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62449303723&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-2707

DO - 10.1158/0008-5472.CAN-08-2707

M3 - Article

C2 - 19244123

AN - SCOPUS:62449303723

VL - 69

SP - 1933

EP - 1940

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 5

ER -